477 related articles for article (PubMed ID: 34203237)
41. Advances in clinical immunotherapy for gastric cancer.
Li K; Zhang A; Li X; Zhang H; Zhao L
Biochim Biophys Acta Rev Cancer; 2021 Dec; 1876(2):188615. PubMed ID: 34403771
[TBL] [Abstract][Full Text] [Related]
42. CAMOIP: a web server for comprehensive analysis on multi-omics of immunotherapy in pan-cancer.
Lin A; Qi C; Wei T; Li M; Cheng Q; Liu Z; Luo P; Zhang J
Brief Bioinform; 2022 May; 23(3):. PubMed ID: 35395670
[TBL] [Abstract][Full Text] [Related]
43. Toward a Taxonomy for Multi-Omics Science? Terminology Development for Whole Genome Study Approaches by Omics Technology and Hierarchy.
Pirih N; Kunej T
OMICS; 2017 Jan; 21(1):1-16. PubMed ID: 28271979
[TBL] [Abstract][Full Text] [Related]
44. New mass spectrometry technologies contributing towards comprehensive and high throughput omics analyses of single cells.
Couvillion SP; Zhu Y; Nagy G; Adkins JN; Ansong C; Renslow RS; Piehowski PD; Ibrahim YM; Kelly RT; Metz TO
Analyst; 2019 Jan; 144(3):794-807. PubMed ID: 30507980
[TBL] [Abstract][Full Text] [Related]
45. Role of Immunotherapy in Triple-Negative Breast Cancer.
Keenan TE; Tolaney SM
J Natl Compr Canc Netw; 2020 Apr; 18(4):479-489. PubMed ID: 32259782
[TBL] [Abstract][Full Text] [Related]
46. Application of immune checkpoint inhibitors in immunotherapy for gastric cancer.
Wu YX; Zhou XY; Wang JQ; Chen GM; Chen JX; Wang RC; Huang JQ; Chen JS
Immunotherapy; 2023 Feb; 15(2):101-115. PubMed ID: 36597704
[TBL] [Abstract][Full Text] [Related]
47. Enhancing immunotherapy in cancer by targeting emerging immunomodulatory pathways.
Kraehenbuehl L; Weng CH; Eghbali S; Wolchok JD; Merghoub T
Nat Rev Clin Oncol; 2022 Jan; 19(1):37-50. PubMed ID: 34580473
[TBL] [Abstract][Full Text] [Related]
48. Single-cell omics in ageing: a young and growing field.
He X; Memczak S; Qu J; Belmonte JCI; Liu GH
Nat Metab; 2020 Apr; 2(4):293-302. PubMed ID: 32694606
[TBL] [Abstract][Full Text] [Related]
49. Multi-omics research strategies in ischemic stroke: A multidimensional perspective.
Li W; Shao C; Zhou H; Du H; Chen H; Wan H; He Y
Ageing Res Rev; 2022 Nov; 81():101730. PubMed ID: 36087702
[TBL] [Abstract][Full Text] [Related]
50. The emerging role of immune checkpoint inhibitors in the treatment of triple-negative breast cancer.
Singh S; Numan A; Maddiboyina B; Arora S; Riadi Y; Md S; Alhakamy NA; Kesharwani P
Drug Discov Today; 2021 Jul; 26(7):1721-1727. PubMed ID: 33745879
[TBL] [Abstract][Full Text] [Related]
51. Metastatic Castration-Resistant Prostate Cancer, Immune Checkpoint Inhibitors, and Beyond.
Lanka SM; Zorko NA; Antonarakis ES; Barata PC
Curr Oncol; 2023 Apr; 30(4):4246-4256. PubMed ID: 37185436
[TBL] [Abstract][Full Text] [Related]
52. Advances in applying of multi-omics approaches in the research of systemic lupus erythematosus.
Song W; Tang D; Chen D; Zheng F; Huang S; Xu Y; Yu H; He J; Hong X; Yin L; Liu D; Dai W; Dai Y
Int Rev Immunol; 2020; 39(4):163-173. PubMed ID: 32138562
[TBL] [Abstract][Full Text] [Related]
53. Application of genomics, proteomics and metabolomics in drug discovery, development and clinic.
Russell C; Rahman A; Mohammed AR
Ther Deliv; 2013 Mar; 4(3):395-413. PubMed ID: 23442083
[TBL] [Abstract][Full Text] [Related]
54. Characterization of outcomes in patients with advanced genitourinary malignancies treated with immune checkpoint inhibitors.
Ma VT; Su CT; Hu M; Taylor JMG; Daignault-Newton S; Kellezi O; Dahl MN; Shah MA; Erickson S; Lora J; Hamasha R; Ali A; Yancey S; Kiros L; Balicki HM; Winfield DC; Green MD; Alva AS
Urol Oncol; 2021 Jul; 39(7):437.e1-437.e9. PubMed ID: 33495117
[TBL] [Abstract][Full Text] [Related]
55. Modulatory effects of gut microbiome in cancer immunotherapy: A novel paradigm for blockade of immune checkpoint inhibitors.
Rezasoltani S; Yadegar A; Asadzadeh Aghdaei H; Reza Zali M
Cancer Med; 2021 Feb; 10(3):1141-1154. PubMed ID: 33369247
[TBL] [Abstract][Full Text] [Related]
56. Omics-based biomarkers: current status and potential use in the clinic.
Quezada H; Guzmán-Ortiz AL; Díaz-Sánchez H; Valle-Rios R; Aguirre-Hernández J
Bol Med Hosp Infant Mex; 2017; 74(3):219-226. PubMed ID: 29382490
[TBL] [Abstract][Full Text] [Related]
57. Multiomics technologies: role in disease biomarker discoveries and therapeutics.
Dar MA; Arafah A; Bhat KA; Khan A; Khan MS; Ali A; Ahmad SM; Rashid SM; Rehman MU
Brief Funct Genomics; 2023 Apr; 22(2):76-96. PubMed ID: 35809340
[TBL] [Abstract][Full Text] [Related]
58. Omics sciences and precision medicine in melanoma.
Medori MC; Donato K; Dhuli K; Maltese PE; Tanzi B; Tezzele S; Mareso C; Miertus J; Generali D; Donofrio CA; Cominetti M; Fioravanti A; Riccio L; Beccari T; Ceccarini MR; Gisondi P; Bellinato F; Stuppia L; Gatta V; Cecchin S; Marceddu G; Bertelli M
Clin Ter; 2023; 174(Suppl 2(6)):29-36. PubMed ID: 37994746
[TBL] [Abstract][Full Text] [Related]
59. Leveraging Multilayered "Omics" Data for Atopic Dermatitis: A Road Map to Precision Medicine.
Ghosh D; Bernstein JA; Khurana Hershey GK; Rothenberg ME; Mersha TB
Front Immunol; 2018; 9():2727. PubMed ID: 30631320
[TBL] [Abstract][Full Text] [Related]
60. Integration of comprehensive genomic profiling, tumor mutational burden, and PD-L1 expression to identify novel biomarkers of immunotherapy in non-small cell lung cancer.
Shi Y; Lei Y; Liu L; Zhang S; Wang W; Zhao J; Zhao S; Dong X; Yao M; Wang K; Zhou Q
Cancer Med; 2021 Apr; 10(7):2216-2231. PubMed ID: 33655698
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
